

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10715055	
	Filing Date		2003-11-17	
	First Named Inventor	Gerald Cagle		
	Art Unit	1618		
	Examiner Name	Fay, Zohreh A.		
	Attorney Docket Number	007109.00001		

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5149693		1992-09-22	Cagle et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20070049552	A1	2007-03-01	Babu et al.	
	2	20060276777	A1	2006-12-07	Coroneo	
	3	20060183698	A1	2006-08-17	Abelson	
	4	20060074053	A1	2006-04-06	Asada et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
-------------------	---------	--------------------------------------	---------------------------	------------------------	------------------	---	--	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10715055
Filing Date	2003-11-17
First Named Inventor	Gerald Cagle
Art Unit	1618
Examiner Name	Fay, Zohreh A.
Attorney Docket Number	007109.00001

1	0001365	WO		2000-01-13	Leo Pharmaceutical Products Ltd.	<input type="checkbox"/>
---	---------	----	--	------------	----------------------------------	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	"Plaintiffs Alcon, Inc.'s and Alcon Manufacturing, Ltd.'s Responsive Interrogatory Concerning Defendant's Supplemental § 112, ¶ 1 Defenses," (1-22-08) Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR)	<input type="checkbox"/>
	2	"Defendant's Supplemental Responses to Plaintiffs' Interrogatories Nos. 3, 7-9, 16, 18, 23, and 24," (11-27-07) Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR)	<input type="checkbox"/>
	3	Pawar et al., AAPS PharmSciTech, 7(1), E1-E6 (2006), "Effect of Formulation Factors on In Vitro Permeation of Moxifloxacin From Aqueous Drops Through Excised Goat, Sheep, and Buffalo Corneas"	<input type="checkbox"/>
	4	Chan et al., Anal. Biochem., 353, 30-36 (2006), "Determination of ofloxacin and moxifloxacin and their penetration in human aqueous and vitreous humor by using high-performance liquid chromatography fluorescence detection"	<input type="checkbox"/>
	5	Expert Report of Eduardo C. Alfonso, M.D. (43 pages; dated 9/19/07) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 (SLR))	<input type="checkbox"/>
	6	Expert Report of Ashim K. Mitra, Ph.D. (27 pages; dated 9/19/07) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 (SLR))	<input type="checkbox"/>
	7	Expert Report of George G. Zhanel, Ph.D. (66 pages; dated 9/19/07) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 (SLR))	<input type="checkbox"/>
	8	Gennaro, Alfonso, R., "19th Edition, Remington: Practice of The Science & Pharmacy, 1995" Ophthalmic Preparations, Chapter 89, pgs. 1563-1576	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10715055
Filing Date	2003-11-17
First Named Inventor	Gerald Cagle
Art Unit	1618
Examiner Name	Fay, Zohreh A.
Attorney Docket Number	007109.00001

9	Trial Transcript for February 28, 2008 for Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 (SLR))	<input type="checkbox"/>
10	Trial Transcript for March 3, 2008 for Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 (SLR))	<input type="checkbox"/>
11	Trial Transcript for March 4, 2008 for Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 (SLR))	<input type="checkbox"/>
12	Trial Transcript for March 5, 2008 for Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 (SLR))	<input type="checkbox"/>
13	Trial Transcript for March 6, 2008 for Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 (SLR))	<input type="checkbox"/>
14	USP Dictionary of USAN and International Drug Names (2000 edition), pg. 479, from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
15	Monograph for Vigamox from the 61st edition of the Physician's Desk Reference, published in 2007, from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
16	Modern Pharmaceutics, 2nd ed. (1990), Ch. 14: Design and Evaluation of Ophthalmic Pharmaceutical Products (Marcel Dekker, Inc., New York), from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
17	Tierney et al., eds., Current Medical Diagnosis & Treatment, 37th ed. (1998), pp. 186, from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
18	Entry for "Ciloxan Solution/Drops; Ophthalmic" in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations; from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
19	Monograph for Ciloxan from the 53rd edition of the Physician's Desk Reference, published in 1999, from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10715055
Filing Date	2003-11-17
First Named Inventor	Gerald Cagle
Art Unit	1618
Examiner Name	Fay, Zohreh A.
Attorney Docket Number	007109.00001

20	Firestone et al., "Solubility characteristics of three fluoroquinolone ophthalmic solutions in an in vitro tear model," Int J. Pharm 164 (1998) 119-128, from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
21	Poster entitled "Synthesis and In Vitro Activity of BAY12-8039, a New 8-Methoxyquinolone" from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
22	Abstract entitled "Synthesis and In Vitro Activity of BAY12-8039, a New 8-Methoxyquinolone,"with associated documents from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
23	Monograph for Ciloxan from the 50th edition of the Physicians' Desk Reference, published in 1996, from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
24	Monograph for Tobradex Ophthalmic Suspension from the 50th edition of the physicians' Desk Reference, published in 1996, from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
25	Entry for "Ciloxan Ointment; Ophthalmic" in the U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, from List of Exhibits to Expert Report of Dr. Loyd V. Allen, Jr.	<input type="checkbox"/>
26	Franz-Josef Schmitz et al., "Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus," Journal of Antimicrobial Chemotherapy (1998) 41, 481-484	<input type="checkbox"/>
27	A. Dalhoff et al, "In vitro Activity of BAY 12-8039, a New 8-Methoxyquinolone,"Chemotherapy 1996; 42: 410-425," Plaintiff's Exhibit 1124; Deposition Exhibit D-124 11-15-07	<input type="checkbox"/>
28	Deposition of David W. Stroman, Ph.D, 6/21/07, Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR)	<input type="checkbox"/>
29	Defendant's Supplemental Notice Pursuant to 35 U.S.C. § 282, 1/25/08, Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR)	<input type="checkbox"/>
30	PTX0059: Confidential letter dated 2/21/06 regarding Patent Certification Notice - U.S. Patent Nos. 4,990,517, 5,607,942, and 6,716,830 Moxifloxacin Hydrochloride Ophthalmic Solution, 0.5% as base, Teva Pharmaceuticals USA, Inc.'s ANDA 78-073, 20 pages, in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10715055
Filing Date	2003-11-17
First Named Inventor	Gerald Cagle
Art Unit	1618
Examiner Name	Fay, Zohreh A.
Attorney Docket Number	007109.00001

31	PTX0086: Excerpt of Kathleen Alford's Lab Notebook (AL0022-000011-014) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
32	PTX0089: Alcon Research Compound Submission (AL007-023353) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
33	PTX0094: Bayer Data (BL002-024345-0024346) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
34	PTX0095: Bayer Data (BL002-029484) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
35	PTX0096: Bayer Data (BL002-030069) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
36	PTX0097: Bayer Data (BL002-031182-031183) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
37	PTX101: Curruculum Vitae of Loyd V. Allen, Ph.D. in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
38	PTX115: Petersen et al., Synthesis and in vitro Activity of BAY 12-8039, A New 8-Methoxy-quinolone, 36th ICAAC (1996) (Abstract) (BL014-011453-011455) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
39	PTX0135: Klugman and Capper, Concentration-dependent Killing of Antibiotic-resistant Pneumococci by the Methoxyquinolone Moxifloxacin, J. Antimicrobial Chemotherapy, 40:797-02 (1997) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
40	PTX0136: Ostergaard et al., Evaluation of Moxifloxacin, a New 8-Methoxyquinolone, for Treatment of Meningitis Caused by a Penicillin-Resistant Pneumococcus in Rabbits, Antimicrobial Agents and Chemotherapy, 42: 1706-12 (1998) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
41	PTX0137: Woodcock et al., In Vitro Activity of Bay 12-8039, A New Fluoroquinolone, Antimicrobial Agents and Chemotherapy, 41(1):101-06 (1997) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10715055
Filing Date		2003-11-17
First Named Inventor	Gerald Cagle	
Art Unit	1618	
Examiner Name	Fay, Zohreh A.	
Attorney Docket Number	007109.00001	

42	PTX0163: Certified Copy of EP Application 0195316 A1, Irikura et al., Quinolonecarboxylic Acid Derivatives (Kyorin) (RT001-012950-012993) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
43	PTX0171: Curriculum Vitae of Dr. George G. Zhanel in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
44	PTX0184-D: Chaudhry et al., Scleral Buckle Infection with Ciprofloxacin-Resistant Pseudomonas aeruginosa, Arch. Ophthalmol., 116:1251 (1998) Date Stamped Copy in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
45	PTX0189: Chaudhry et al., Emerging Ciprofloxacin-Resistant Pseudomonas aeruginosa, Am. J. Ophthalmology, 128 (4):509-10 (1999) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs Exhibit List)	<input type="checkbox"/>
46	PTX0194-D: Ball et al., Therapeutic Advances of New Fluoroquinolones, Expert Opinion on Investigational Drugs, 7 (5):761-83 (1998) Date Stamped Copy in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs' Exhibit List)	<input type="checkbox"/>
47	PTX0209: Leophonte et al., Trovafloxacin Versus Amoxicillin/Clavulanic Acid in the Treatment of Acute Exacerbations of Chronic Obstructive Bronchitis, Eur. J. Clin. Microbiol. Infect. Dis., 17:434-40 (1998) in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR) (Plaintiffs Exhibit List)	<input type="checkbox"/>
48	PTX2030I: Powerpoint slide: Some Compounds are Maintained Longer in the Aqueous Humor in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR)	<input type="checkbox"/>
49	PTX2031A: Powerpoint slide: Moxifloxacin In Solution in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR)	<input type="checkbox"/>
50	PTX2031B: Powerpoint slide: Moxifloxacin In Solution in Bayer Healthcare AG, Alcon, Inc., and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc. (Civil Action No. 06-234 SLR)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10715055
Filing Date	2003-11-17
First Named Inventor	Gerald Cagle
Art Unit	1618
Examiner Name	Fay, Zohreh A.
Attorney Docket Number	007109.00001

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.